Semaglutide
A GLP-1 receptor agonist commonly evaluated for medical weight management and metabolic support.
Every listing is educational. A licensed provider decides suitability, dosing, and monitoring during a live consultation.
A GLP-1 receptor agonist commonly evaluated for medical weight management and metabolic support.
GHRH and GHRP combination studied for pulsatile growth hormone release.
Coenzyme central to cellular energy, sirtuin activation, and DNA-repair pathways.
Immunomodulatory peptide studied for T-cell function.
GHRH analog studied for stimulation of the body's own growth hormone.
Modified GH fragment studied for lipolysis in research settings.
Neuropeptide sometimes discussed for mood, bonding, and intimacy support in provider-directed protocols.
Orally active ghrelin receptor agonist studied for GH/IGF-1 secretion.
Peptide fragment studied primarily in preclinical models for tissue repair.
Copper-binding tripeptide studied for skin and hair follicle signaling.
Melanocortin receptor agonist with an FDA-approved indication in premenopausal women; other uses discussed with providers.
Mitochondrial-derived peptide studied in metabolic homeostasis research.
Dual GIP/GLP-1 receptor agonist evaluated for weight and cardiometabolic health.
GHRH analog with FDA approval for a specific HIV-related indication; sometimes discussed off-label.
Endogenous tripeptide antioxidant used clinically in select settings.
Neuroendocrine peptide studied in hypothalamic-pituitary-gonadal signaling.
Tetrapeptide studied for telomerase activity and circadian rhythm.
Compounded topical/injectable blend discussed for aesthetic and repair applications.
Compounded aesthetic blend evaluated case-by-case.
Investigational triple agonist (GLP-1 / GIP / glucagon) studied for weight management. NOT FDA-approved.
A compounded blend of two Russian-developed neuropeptides studied individually in preclinical and limited human models for cognitive and stress-regulatory effects. Neither is FDA-approved.
A branded compounded blend combining BPC-157 and TB-500, two research peptides individually studied in preclinical models for tissue repair. Neither component is FDA-approved; this specific combination has not been evaluated in clinical trials as a combination.